Akero Therapeutics, Inc. (AKRO) analyst actions
AKRO analyst actions moved a median of -0.73% by the close. Rating and price-target actions on AKRO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the AKRO overview →
14 measured AKRO analyst action events.
Where these AKRO analyst actions landedvs 14 measured AKRO analyst action reactions
| Middle 50% of AKRO analyst action reactions | -1.70% to +0.92% |
|---|---|
| Median reaction (to close) | -0.73% |
| Measured reactions | 14 |
Point-in-time · zero look-ahead
Half of the 14 AKRO analyst action events with a measured close landed between -1.70% and +0.92%; 43% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out | Press release | +0.13% | -0.23% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out | Press release | -2.98% | +0.85% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out | Press release | +0.00% | +0.94% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out | Press release | +0.23% | -1.68% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out | Press release | +0.64% | +1.01% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out | Press release | -0.09% | -1.51% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out | Press release | -0.50% | -3.25% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out | Press release | -1.00% | -1.23% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out | Press release | +0.62% | -1.71% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out | Press release | -0.44% | +0.97% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out | Press release | -2.20% | -7.78% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out | Press release | +0.44% | +0.41% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out | Press release | -0.74% | -2.91% | |
| Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH | Press release | +1.02% | +3.49% |
Keep exploring
More AKRO: earnings → · SEC filings → · AKRO overview →